S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Canada Goose is Projecting Optimism, but Investors Aren’t Buying
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
New "Mined in America" Lithium Opportunities? (Ad)
Arista Networks Soars As Investors Spot Opportunity After Selloff
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Canada Goose is Projecting Optimism, but Investors Aren’t Buying
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
New "Mined in America" Lithium Opportunities? (Ad)
Arista Networks Soars As Investors Spot Opportunity After Selloff
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Canada Goose is Projecting Optimism, but Investors Aren’t Buying
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
New "Mined in America" Lithium Opportunities? (Ad)
Arista Networks Soars As Investors Spot Opportunity After Selloff
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Canada Goose is Projecting Optimism, but Investors Aren’t Buying
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
New "Mined in America" Lithium Opportunities? (Ad)
Arista Networks Soars As Investors Spot Opportunity After Selloff
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Forecast, Price & News

$2.32
-0.05 (-2.11%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$2.31
$2.40
50-Day Range
$2.32
$58.32
52-Week Range
$2.29
$220.80
Volume
28,400 shs
Average Volume
1.63 million shs
Market Capitalization
$2.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Ensysce Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
546.6% Upside
$15.00 Price Target
Short Interest
Bearish
11.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Ensysce Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$44,235 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($13.00) to ($15.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars


ENSC stock logo

About Ensysce Biosciences (NASDAQ:ENSC) Stock

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

ENSC: ENSC Provides an Attractive Entry Point
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
See More Headlines
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Company Calendar

Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENSC
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+546.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,170,000.00
Net Margins
-944.85%
Pretax Margin
-938.73%

Debt

Sales & Book Value

Annual Sales
$2.52 million
Book Value
($7.54) per share

Miscellaneous

Free Float
779,000
Market Cap
$2.97 million
Optionable
Not Optionable
Beta
0.58

Key Executives

  • Dr. D. Lynn Kirkpatrick Ph.D. (Age 65)
    Pres, CEO & Director
    Comp: $288.15k
  • Mr. David C. Humphrey CPA (Age 54)
    CFO, Sec. & Treasurer
    Comp: $308.41k
  • Mr. Geoffrey Birkett (Age 60)
    Chief Commercial Officer
    Comp: $135k
  • Dr. Jeffrey Millard Ph.d. (Age 47)
    Chief Operating Officer
  • Mr. Richard Wright M.B.A. (Age 50)
    MSE, Chief Bus. Officer
  • Dr. William K. Schmidt Ph.D. (Age 71)
    Chairman of Clinical Advisory Board & Chief Medical Officer
  • Dr. Linda Pestano Ph.D. (Age 53)
    Chief Devel. Officer













ENSC Stock - Frequently Asked Questions

Should I buy or sell Ensysce Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENSC shares.
View ENSC analyst ratings
or view top-rated stocks.

What is Ensysce Biosciences' stock price forecast for 2023?

1 equities research analysts have issued 1 year target prices for Ensysce Biosciences' stock. Their ENSC share price forecasts range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 546.6% from the stock's current price.
View analysts price targets for ENSC
or view top-rated stocks among Wall Street analysts.

How have ENSC shares performed in 2023?

Ensysce Biosciences' stock was trading at $9.00 at the beginning of the year. Since then, ENSC stock has decreased by 74.2% and is now trading at $2.32.
View the best growth stocks for 2023 here
.

Are investors shorting Ensysce Biosciences?

Ensysce Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 113,600 shares, an increase of 43.8% from the April 30th total of 79,000 shares. Based on an average daily volume of 664,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 11.0% of the shares of the company are sold short.
View Ensysce Biosciences' Short Interest
.

When is Ensysce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ENSC earnings forecast
.

When did Ensysce Biosciences' stock split?

Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Ensysce Biosciences' stock symbol?

Ensysce Biosciences trades on the NASDAQ under the ticker symbol "ENSC."

Who are Ensysce Biosciences' major shareholders?

Ensysce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (1.05%).
View institutional ownership trends
.

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ensysce Biosciences' stock price today?

One share of ENSC stock can currently be purchased for approximately $2.32.

How much money does Ensysce Biosciences make?

Ensysce Biosciences (NASDAQ:ENSC) has a market capitalization of $2.97 million and generates $2.52 million in revenue each year. The company earns $-24,170,000.00 in net income (profit) each year or ($139.5350) on an earnings per share basis.

How can I contact Ensysce Biosciences?

Ensysce Biosciences' mailing address is 250 WEST 57 TH STREET SUITE 415, NEW YORK NY, 10107. The official website for the company is ensysce.com. The company can be reached via phone at 858-263-4196 or via email at shannon@mzgroup.us.

This page (NASDAQ:ENSC) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -